AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04974190 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Spray Device
Description: A Nasal Spray apparatus containing a liquid
Study NCT05559866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo ESG with ERBE HAPC
Description: Utilizing two approved devices in combination to assess durability of suturing.
Study NCT06437483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained Natural Apophyseal Glides
Description: SNAGs:~Therapist will apply an antero-superior accessory glide to the superior spinous process of the involved motion segment (between C3 to C7) by pushing it towards the direction of eyeball at approximately a 45 degree angle, using the thumb. The other thumb will reinforce the glide. Painless accessory glide will be maintained and subject will slowly turn their head towards the painful or restricted side (that elicited symptoms) and sustain the position for a few seconds. In case of symptom-free, the subject will apply overpressure at the end of restricted range of motion. The glide will be maintained till the head returns to the midline.~Each session will consist of three sets of six to ten repetitions.
Study NCT06437483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Natural Apophyseal Glides
Description: SNAGs:~Therapist will apply an antero-superior accessory glide to the superior spinous process of the involved motion segment (between C3 to C7) by pushing it towards the direction of eyeball at approximately a 45 degree angle, using the thumb. The other thumb will reinforce the glide. Painless accessory glide will be maintained and subject will slowly turn their head towards the painful or restricted side (that elicited symptoms) and sustain the position for a few seconds. In case of symptom-free, the subject will apply overpressure at the end of restricted range of motion. The glide will be maintained till the head returns to the midline.~Each session will consist of three sets of six to ten repetitions.
Study NCT06437483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Kinesiotaping (KT):~Subject will be in comfortable sitting position. Neck of the subject will be thoroughly cleaned with alcohol and sterile gauze pads before the application of Kinesiotape.The layers of KT will be applied in the form of two strips i.e. Y strip and I strip. and applied over the neck in a position of cervical flexion and contralateral rotation and, pasted up and over either ridge of the spine covering the cervical muscles.It extends from T1-T2 to either side of C1-C2.The second layer is I-strip:The overlaying I-strip will be placed perpendicular to the Y-strip, It will be stretched from the both ends, and the middle portion of the tape will be applied first after which tension is released and ends are applied without tension.
Study NCT06437483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Hot pack (moist heat) and TENS will be applied, each for 10 minutes.
Study NCT06437483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Hot pack (moist heat) and TENS will be applied, each for 10 minutes.
Study NCT04129073 — intervention group
Intervention type: OTHER
Intervention: Intensive care treatment
Description: Intensive care treatment; Utilization of neuroprognostication tools
Study NCT05559866 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apollo ESG
Description: Using only Apollo ESG as approved per label.
Study NCT05987423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Satralizumab will be administered by SC injection.
Study NCT05987423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by SC injection
Study NCT06003712 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants will engage in a 10-15 minute mindfulness exercise three times weekly for one month. This mindfulness exercise utilizes guided attention on the breath through an instructional video, aiming to cultivate calmness and alleviate stress.
Study NCT05080790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab Beta, Zoledronic acid, Interleukin-2
Description: Five 5-week cycles (Q5W) of dinutuximab beta, zoledronic acid and low-dose interleukin (IL-2)
Study NCT06184256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Core Curriculum
Description: 12-week core nutrition education curriculum + 12-week tapered maintenance curriculum
Study NCT06184256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - 1:1 Counseling
Description: Individual 1:1 counseling sessions with a registered dietitian
Study NCT05029336 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depletion of CD3/CD19 in an autologous stem cell transplant
Description: The purpose of this study is to determine the safety and feasibility of CD3/CD19 depleted autologous stem cell transplant for the treatment of life threatening autoimmune disease. We will perform CD3/CD19 depletion using the CliniMACs device as a means of purging autoreactive T and B cells from the transfused autologous stem cell product, while retaining some immune function, namely natural killer cells and monocytes in the product.
Study NCT06184256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Behavioral Skills
Description: Group-based behavioral skills development sessions
Study NCT06241833 — intervention group
Intervention type: DRUG
Intervention: PPI
Description: use of PPI concomitant with DAPT
Study NCT06211166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Digital PCR
Description: digital Polymerase Chain Reaction (dPCR)
Study NCT06211166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative PCR
Description: Real-time Polymerase Chain Reaction (real-time PCR)
Study NCT06211166 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MFC
Description: Multicolor Flow Cytometry
Study NCT05403281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW6012
Description: Drug: DW6012 Single oral administration of DW6012 after an overnight fast~Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast
Study NCT05960136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lift in patients with positive COVID-19 history
Description: Sinus augmentation in the posterior atrophic maxilla in patients with positive COVID-19 history
Study NCT05960136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lift with negative COVID-19 history
Description: Sinus augmentation in the posterior atrophic maxilla in patients with negative COVID-19 history
Study NCT05591651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of damaged nipple skin: Preparation with hyaluronic acid
Description: The active preparation will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
Study NCT05591651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of damaged nipple skin: Neutral preparation without hyaluronic acid
Description: The neutral preparation, containing only white vaseline, will be applied for five days, locally on the damaged nipple skin after every second breastfeeding session, and at least four times in 24 hours, alternating it with breast milk.
Study NCT06325540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indirect pulp capping with theracal pt
Description: indirect pulp capping using the theracal pt material
Study NCT06184256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BfedBwell - Group Support
Description: Structured group support sessions
Study NCT06184256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program delivery
Description: Delivery and evaluation of one or more intervention components
Study NCT05347472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone application
Description: the smartphone application intervention will consist daily physical therapy exercises program. The application will include all the videos about the exercises and all information about the repetition, frequency, intensity, and position.
Study NCT05347472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Smartphone application
Description: ham application that includes information and general advice about UI only
Study NCT06325540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indirect pulp capping with therabase
Description: indirect pulp capping using the therabase material
Study NCT06325540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: indirect pulp capping with biodentine
Description: indirect pulp capping using the biodentine material
Study NCT06637865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP761
Description: intravenous
Study NCT06637865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous
Study NCT06637865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: keyhole limpet haemocyanin (KLH)
Description: intramuscular immunization and intradermal challenge
Study NCT06637865 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: keyhole limpet haemocyanin (KLH)
Description: intramuscular immunization and intradermal challenge
Study NCT06581406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP2
Description: Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.
Study NCT06581406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab: human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody
Study NCT06581406 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab: Anti-PD-1 Monoclonal antibody
Study NCT04747431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBFT02
Description: PBFT02
Study NCT05825989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Beat Acupunch Regimen
Description: The Healthy Beat Acupunch (HBA) regimen, developed by Chen et al. (2017), is based on the Meridian Theory or Jing-Luo Theory. The HBA regimen focuses on body movement with hands swinging, resulting in the natural swinging of fists that hit on acupoints. There are three phases: phase 1 is activating qi and blood; phase 2 is punching meridians; phase 3 is relaxing body and mind.
Study NCT05078671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: olaparib treatment
Study NCT05078671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: olaparib treatment
Study NCT05078671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Pharmacokinetic booster
Study NCT04787926 — intervention group
Intervention type: DEVICE
Intervention: Locking Solution
Description: The total duration of the study treatment period will be 90 calendar days, from Visit 1 Pre-Instillation to the last study-related assessment. Two to 3 instillations (1 per lumen per visit) of DuraLock-C 4.0%, 30.0%, or 46.7% (equivalent to the catheter manufacturer's prescribed priming volume) will be instilled 1 to 3 days apart (with a HD schedule of 3 to 4 times per week); each instillation of CLS will remain in the CVC for approximately 24 to 72 hours ± 12 hours, based on their practice preferences. EOS will take place at the patient's next scheduled dialysis session.
Study NCT04713553 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection
Study NCT04713553 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2.B.1.351
Description: Intramuscular injection
Study NCT04975009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear conditioning
Description: Participants will learn to associate neutral stimuli with a mildly uncomfortable electrical stimulation to the wrist. The intensity of the electrical stimulus is calibrated prior to the start of the experiment to a level deemed highly annoying but not painful by the participant.
Study NCT05321693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Pulsed Current Stimulation
Description: Current has a peak pulse amplitude of 2mA, with a frequency range from 6 to 10 Hz. A battery-powered current stimulator will be used. This device provides stimulation through biphasic and alternating square wave pulse, with random pulse width range from 1 to 20 ms
Study NCT05321693 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Pulsed Current Stimulation
Description: Current has a peak pulse amplitude of 2mA, with a frequency range from 6 to 10 Hz. A battery-powered current stimulator will be used. This device provides stimulation through biphasic and alternating square wave pulse, with random pulse width range from 1 to 20 ms
Study NCT06309966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
Study NCT06309966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 75 mg. Participants will take blinded investigational product (IP) once daily
Study NCT06309966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo taken once daily
Study NCT06380751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saruparib (AZD5305)
Description: Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.
Study NCT05878145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured rehabilitation exercise program
Description: Stretching (10 mins): neck, shoulder, wrist, back; Aerobic exercise (20 mins): cycle ergometer, wheelchair run; Strengthening exercise (15 mins): shoulder press, chest press, front raise, biceps curl, lateral raise, bent over rowing or rowing, bent over lateral raise, triceps extension; Balance training (5 mins); Stretching exercise (10 mins)
Study NCT04758169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Homestead Food Production
Description: Enhanced Homestead Food Production program will provide increased production and consumption of nutrient rich foods, increased income of the households through the sale of surplus produce, and increased self-efficacy and decision making by adolescents due to increased knowledge and skills- resulting increased food security and nutrition and ultimately delay of child marriage.
Study NCT04758169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group will only receive parental awareness sessions, community awareness-raising activities, adolescent group sessions involving awareness on the benefit of delayed marriage and empowerment, SRH, and basic life-skill trainings.
Study NCT04678271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AFIX-OB Quality Improvement Package
Description: Practices randomized to the intervention arm will be provided with a package of core and supplemental quality improvement interventions to choose from so that the most effective combination for their practice is implemented. Each practice will be required to implement a tablet-based educational app for patients, and evidence based online educational module for providers, standing order protocol, and a reminder/recall protocol. They can then choose to also use flyers and posters in their waiting rooms, standardized talking points for maternal immunization for the providers, educational content for the practice website, and laminated and highlighted CDC Vaccine Information Sheets. The recruited patients and providers at the practice will be given a baseline and follow-up survey to assess their knowledge, attitudes, and beliefs towards maternal immunization.
Study NCT04700371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interwoven stent
Description: Interwoven nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
Study NCT04700371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser-cut stent
Description: Laser-cut nitinol stent placement in patients with arteriosclerotic lesions of the distal portion of the superficial artery and/or the popliteal artery.
Study NCT06088732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Session
Description: 30 min cycling on bicycle ergometer at 60% peak power output
Study NCT06088732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Session
Description: 30 min cycling on bicycle ergometer at 60% peak power output
Study NCT06088732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Description: A single oral dose of Ibuprofen
Study NCT06088732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 800 mg
Description: A single oral dose of Ibuprofen
Study NCT06088732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rest
Description: Resting for 30 min in chair
Study NCT06088732 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rest
Description: Resting for 30 min in chair
Study NCT06088732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT06088732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT04218825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlormethine gel
Description: Gel to be applied to all skin areas affected by MF-CTCL
Study NCT05783492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Description: 10 mg/kg single dose in 0.5 mL sprays in each nare separated by 60 seconds
Study NCT05193851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ricolinostat
Description: This study is an open-label, single-dose phase I clinical study to evaluate the safety and pharmacokinetics of ricolinostat in healthy Chinese adult subjects.~12 subjects are planned to be enrolled, both male and female, and all will receive the investigational drug.~This study includes the screening period, baseline period, dosing/observation period, discharge and follow-up period.
Study NCT06362395 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)
Description: Precise radiation therapy delivered in a single session using magnetic resonance imaging for guidance.
Study NCT06362395 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)
Description: Precise radiation therapy delivered in a single session using magnetic resonance imaging for guidance.
Study NCT05278936 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The cataract surgery and the anterior vitrectomy
Description: Surgical
Study NCT05713968 — intervention group
Intervention type: OTHER
Intervention: patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM
Description: patients with EAT-10 higher than 3 or frailty questionnaire higher than 2 examined by HRIM
Study NCT05713968 — intervention group
Intervention type: OTHER
Intervention: patients with EAT-10 lower than 3 or frailty questionnaire lower than 2
Description: patients with EAT-10 lower than 3 or frailty questionnaire lower than 2 examined by HRIM
Study NCT06380348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101 Injection
Description: JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 days
Study NCT06380348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib tablet
Description: Osimertinib 160mg once po everyday
Study NCT06380348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin injection
Description: Cisplatin 75mg/m\^2, IV infusion, on day-1 at every cycle of 21days, 4 cycles at most.
Study NCT06380348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed injection
Description: Pemetrexed 500mg/m\^2, IV infusion, on day-1 at every cycle of 21 days.
Study NCT05226143 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gel Cream
Description: Gel Cream
Study NCT06165861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental (with VR-G)
Description: Watching video with using VR-G before undergoing open heart surgery
Study NCT05410977 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples
Study NCT05410977 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records reviewed
Study NCT04907812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Patients will receive 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride before your surgery and 1 gram dose of intravenous (IV) tranexamic acid mixed with 50cc 0.9% sodium chloride 3-6 hours after your first dose on the day of your surgery